메뉴 건너뛰기




Volumn 24, Issue 9, 2009, Pages 1319-1324

Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies

Author keywords

Entacapone; Levodopa; Motor fluctuation; Parkinson's disease; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA;

EID: 69549103564     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22587     Document Type: Article
Times cited : (44)

References (19)
  • 1
    • 69549118227 scopus 로고    scopus 로고
    • LeWitt P. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne D, editor. Drugs for the treatment of Parkinson's disease, 88. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 1989. p325-384.
    • LeWitt P. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne D, editor. Drugs for the treatment of Parkinson's disease, Vol.88. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 1989. p325-384.
  • 2
    • 0020059227 scopus 로고
    • Alternate day levodopa therapy in Parkinsonism
    • Koller WC. Alternate day levodopa therapy in Parkinsonism. Neurology 1982;32:324-326.
    • (1982) Neurology , vol.32 , pp. 324-326
    • Koller, W.C.1
  • 3
    • 9044226896 scopus 로고    scopus 로고
    • Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa
    • Parkinson Study Group
    • Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45.
    • (1996) Ann Neurol , vol.39 , pp. 37-45
  • 4
    • 28444499344 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease
    • Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005;32: 459-484.
    • (2005) J Pharmacokinet Pharmacodyn , vol.32 , pp. 459-484
    • Chan, P.L.1    Nutt, J.G.2    Holford, N.H.3
  • 5
    • 0018892695 scopus 로고
    • Changes in neostriatal dopamine concentrations in response to levodopa infusions
    • Doller HJ, Connor JD. Changes in neostriatal dopamine concentrations in response to levodopa infusions. J Neurochem 1980;34: 1264-1269.
    • (1980) J Neurochem , vol.34 , pp. 1264-1269
    • Doller, H.J.1    Connor, J.D.2
  • 6
    • 0033546661 scopus 로고    scopus 로고
    • Pharmacodynamics of the long-duration response to levodopa in PD
    • Zappia M, Bosco D, Plastino M, et al. Pharmacodynamics of the long-duration response to levodopa in PD. Neurology 1999;53: 557-560.
    • (1999) Neurology , vol.53 , pp. 557-560
    • Zappia, M.1    Bosco, D.2    Plastino, M.3
  • 7
    • 0024829604 scopus 로고
    • Controlled-release carbidopa/ levodopa (Sinemet 50/200 CR4): Clinical and pharmacokinetic studies
    • LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/ levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(suppl 2):45-53.
    • (1989) Neurology , vol.39 , Issue.SUPPL. 2 , pp. 45-53
    • LeWitt, P.A.1    Nelson, M.V.2    Berchou, R.C.3
  • 8
    • 0024520481 scopus 로고
    • A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance
    • Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989;52:207-212.
    • (1989) J Neurol Neurosurg Psychiatry , vol.52 , pp. 207-212
    • Cedarbaum, J.M.1    Hoey, M.2    McDowell, F.H.3
  • 9
    • 0034968037 scopus 로고    scopus 로고
    • The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
    • Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol 2001;24:150-157.
    • (2001) Clin Neuropharmacol , vol.24 , pp. 150-157
    • Heikkinen, H.1    Nutt, J.G.2    LeWitt, P.A.3
  • 10
    • 0000224448 scopus 로고
    • Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale
    • Fahn S, Marsden DM, Goldstein M, Calne DB, editors, New York: MacMillan;
    • Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden DM, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, Vol.2. New York: MacMillan; 1987. p153-163.
    • (1987) Recent developments in Parkinson's disease , vol.2 , pp. 153-163
    • Fahn, S.1    Elton, R.L.2
  • 11
    • 0033995552 scopus 로고    scopus 로고
    • A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
    • Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
    • (2000) Clin Neuropharmacol , vol.23 , pp. 75-81
    • Hauser, R.A.1    Friedlander, J.2    Zesiewicz, T.A.3
  • 12
    • 0025162198 scopus 로고
    • Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/ levodopa (Sinemet CR4) in Parkinson's disease
    • Nelson MV, Berchou RC, LeWitt PA, et al. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/ levodopa (Sinemet CR4) in Parkinson's disease. Neurology 1990;40:70-74.
    • (1990) Neurology , vol.40 , pp. 70-74
    • Nelson, M.V.1    Berchou, R.C.2    LeWitt, P.A.3
  • 13
    • 0028891614 scopus 로고
    • Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers
    • Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
    • (1995) Clin Neuropharmacol , vol.18 , pp. 46-57
    • Ahtila, S.1    Kaakkola, S.2    Gordin, A.3
  • 14
    • 33748934417 scopus 로고    scopus 로고
    • Pharmacokinetic behavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/ carbidopa with and without entacapone in patients with Parkinson's disease
    • Müller T, Erdmann C, Muhlack S, et al. Pharmacokinetic behavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/ carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113:1441-1448.
    • (2006) J Neural Transm , vol.113 , pp. 1441-1448
    • Müller, T.1    Erdmann, C.2    Muhlack, S.3
  • 15
    • 0028137620 scopus 로고
    • Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease
    • Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
    • (1994) J Neurol Neurosurg Psychiatry , vol.57 , pp. 186-189
    • Merello, M.1    Lees, A.J.2    Webster, R.3
  • 16
    • 21544474680 scopus 로고    scopus 로고
    • Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR
    • Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol 2005;28:115-119.
    • (2005) Clin Neuropharmacol , vol.28 , pp. 115-119
    • Paija, O.1    Laine, K.2    Kultalahti, E.R.3
  • 17
    • 0034058782 scopus 로고    scopus 로고
    • The catechol-Omethyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
    • Piccini P, Brooks DJ, Korpela K, et al. The catechol-Omethyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-594.
    • (2000) J Neurol Neurosurg Psychiatry , vol.68 , pp. 589-594
    • Piccini, P.1    Brooks, D.J.2    Korpela, K.3
  • 18
    • 36148978164 scopus 로고    scopus 로고
    • Comparison of 200 mg retarded release levodopa/carbidop - with 150 mg levodopa/carbidopa/ entacapone application: Pharmacokinetics and efficacy in patients with Parkinson's disease
    • Müller T, Ander L, Kolf K, Woitalla D, Muhlack S. Comparison of 200 mg retarded release levodopa/carbidop - with 150 mg levodopa/carbidopa/ entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. J Neural Transm 2007;114:1457-1462.
    • (2007) J Neural Transm , vol.114 , pp. 1457-1462
    • Müller, T.1    Ander, L.2    Kolf, K.3    Woitalla, D.4    Muhlack, S.5
  • 19
    • 0014082977 scopus 로고
    • Parkinsonism: Onset, progression, and mortality
    • Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
    • (1967) Neurology , vol.17 , pp. 427-442
    • Hoehn, M.M.1    Yahr, M.D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.